John R. Moore, General Counsel of Edgewise Therapeutics ($EWTX), sold about $60,000 worth of company shares in two open market transactions over the past year. His most recent sale occurred on August 12, 2025. These sales rank 10,198th among 11,678 insiders in our database, where the average is $8.6 million across roughly six transactions. Moore made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | A | Stock Option (Right to Buy) | 161250 | $0.00 | 161,250.0000 | 104,940,493 | 9999.99% | 0.15% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 5781 | $0.00 | 12,312.0000 | 104,940,493 | 88.52% | 0.01% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 2098 | $13.39 | 10,214.0000 | 104,940,493 | 17.04% | 0.00% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Restricted Stock Units | 5781 | $0.00 | 17,344.0000 | 104,940,493 | 25.00% | 0.01% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | A | Restricted Stock Units | 26875 | $0.00 | 26,875.0000 | 104,940,493 | 9999.99% | 0.03% |
| May 2, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 1930 | $16.45 | 6,531.0000 | 95,130,053 | 22.81% | 0.00% |
| May 1, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 5209 | $0.00 | 8,461.0000 | 95,130,053 | 160.18% | 0.01% |
| May 1, 2025 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Restricted Stock Units | 5209 | $0.00 | 0.0000 | 95,130,053 | 100.00% | 0.01% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 50000 | $0.71 | 53,252.0000 | 93,515,356 | 1537.52% | 0.05% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 50000 | $28.37 | 3,252.0000 | 93,515,356 | 93.89% | 0.05% |
| Sept. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 20922 | $0.71 | 24,174.0000 | 93,515,356 | 643.36% | 0.02% |
| Sept. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 20922 | $27.63 | 3,252.0000 | 93,515,356 | 86.55% | 0.02% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Stock Option (Right to Buy) | 50000 | $0.00 | 62,558.0000 | 93,515,356 | 44.42% | 0.05% |
| Sept. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Stock Option (Right to Buy) | 20922 | $0.00 | 41,636.0000 | 93,515,356 | 33.44% | 0.02% |
| Aug. 12, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | A | Stock Option (Right to Buy) | 138750 | $0.00 | 138,750.0000 | 93,515,356 | 9999.99% | 0.15% |
| Aug. 12, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | A | Restricted Stock Units | 23125 | $0.00 | 23,125.0000 | 93,515,356 | 9999.99% | 0.02% |
| May 1, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 5208 | $0.00 | 5,208.0000 | 87,567,307 | 9999.99% | 0.01% |
| May 2, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 1956 | $18.91 | 3,252.0000 | 87,567,307 | 37.56% | 0.00% |
| May 1, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Restricted Stock Units | 5208 | $0.00 | 5,209.0000 | 87,567,307 | 50.00% | 0.01% |
| Feb. 7, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 17993 | $1.93 | 17,993.0000 | 63,723,600 | 9999.99% | 0.03% |
| Feb. 7, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 17993 | $20.00 | 0.0000 | 63,723,600 | 100.00% | 0.03% |
| Feb. 8, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 3813 | $1.93 | 3,813.0000 | 63,723,600 | 9999.99% | 0.01% |
| Feb. 8, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 3813 | $20.01 | 0.0000 | 63,723,600 | 100.00% | 0.01% |
| Feb. 9, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Common Stock | 8029 | $1.93 | 8,029.0000 | 63,723,600 | 9999.99% | 0.01% |
| Feb. 9, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | S | Common Stock | 8029 | $20.01 | 0.0000 | 63,723,600 | 100.00% | 0.01% |
| Feb. 7, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Stock Option (Right to Buy) | 17993 | $0.00 | 105,004.0000 | 63,723,600 | 14.63% | 0.03% |
| Feb. 8, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Stock Option (Right to Buy) | 3813 | $0.00 | 101,191.0000 | 63,723,600 | 3.63% | 0.01% |
| Feb. 9, 2024 | Edgewise Therapeutics, Inc. | $EWTX | MOORE JOHN R | General Counsel | M | Stock Option (Right to Buy) | 8029 | $0.00 | 93,162.0000 | 63,723,600 | 7.93% | 0.01% |